Table 1.
Demographic | All (224) | Low SMD (116) | High SMD (108) | Low vs. High SMD p‐value | ||
---|---|---|---|---|---|---|
Low BMI (43) | High BMI (73) | Low BMI (38) | High BMI (70) | |||
Age at diagnosis, median (years) | 62 (21–88) | 65 | 69 | 49 | 56 | <0.0001 |
Sex, # | 0.02 | |||||
Male | 125 (56%) | 19 (44%) | 34 (47%) | 25 (66%) | 47 (59%) | |
Female | 99 (44%) | 24 (56%) | 39 (53%) | 13 (34%) | 23 (41%) | |
Body weight, median (kg) | 75.7 | 61.7 | 83.3 | 61.8 | 78.8 | <0.0001 |
Body mass index, median (kg/m2) | 26.8 | 22.5 | 30.1 | 22.2 | 28.0 | <0.0001 |
Stage, # | 0.24 | |||||
I | 50 (22%) | 8 (19%) | 13 (18%) | 6 (16%) | 23 (33%) | |
II | 44 (20%) | 5 (12%) | 13 (18%) | 12 (32%) | 14 (20%) | |
III | 27 (12%) | 4 (9%) | 13 (18%) | 3 (8%) | 7 (10%) | |
IV | 103 (46%) | 26 (60%) | 34 (47%) | 17 (45%) | 26 (33%) | |
R‐IPI, # | 0.0001 | |||||
0 | 18 (8%) | 0 | 2 (3%) | 8 (21%) | 8 (11%) | |
1 | 44 (20%) | 5 (12%) | 12 (16%) | 9 (24%) | 18 (26%) | |
2 | 48 (21%) | 6 (14%) | 14 (19%) | 5 (13%) | 23 (33%) | |
3 | 58 (26%) | 18 (42%) | 21 (29%) | 7 (18%) | 12 (17%) | |
4 | 40 (18%) | 8 (19%) | 15 (21%) | 9 (24%) | 8 (11%) | |
5 | 16 (7%) | 6 (14%) | 9 (12%) | 0 | 1 (1%) | |
Chemoimmunotherapy cycles received, median | 6 | 6 | 6 | 6 | 6 | |
Best response to chemoimmunotherapy, # | 0.04 | |||||
Complete response | 168 (75%) | 30 (70%) | 46 (63%) | 31 (82%) | 61 (87%) | 0.0007 |
Partial response | 41 (18%) | 9 (21%) | 21 (29%) | 7 (18%) | 4 (6%) | |
Stable disease | 2 (0.1%) | 1 (2%) | 0 | 0 | 1 (1%) | |
Progressive disease | 13 (6%) | 3 (7%) | 6 (8%) | 0 | 4 (6%) | |
Required at least 1 cycle delayed, # | 90 (40%) | 17 (40%) | 30 (41%) | 18 (47%) | 25 (36%) | 0.78 |
CT measures | ||||||
Median skeletal muscle area (cm2) | 130.7 | 109.1 | 126.0 | 127.6 | 157.6 | <0.0001 |
Median skeletal muscle index (SMI, cm2/m2) | 47.7 | 40.4 | 46.5 | 45.0 | 54.3 | <0.0001 |
SMD (HU) | 34.1 | 32.9 | 25.0 | 45.5 | 38.9 | <0.0001 |